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Does  a low  FODMAP  diet  improve  symptoms  in Mexican
patients with  IBS?,
¿Una  dieta  baja  en  FODMAP  mejora  los  síntomas  en  pacientes  mexicanos
con  SII?
l
t
s
a
f
s
a
o
l
a
s
i
g
p
1
u
i
d
2
b
a
s
N
i
t
d
t
T
p
i
T
aDespite  the  fact  that  the  majority  of  patients  with  irritable
bowel  syndrome  (IBS)  complain  that  foods  trigger  or  exac-
erbate  their  symptoms,1 the  role  of  diet  in  IBS  has  not  been
adequately  studied.  It  is  very  common  for  IBS  patients  to
experiment  with  changes  in  their  diet  or  limit  the  intake
of  certain  foods,  even  before  seeking  medical  attention.2
The  most  frequently  implicated  foods  are  wheat,  corn,  dairy
products,  coffee,  tea,  and  citrus  fruits.  Therefore,  it  is  not
surprising  that  in  a  study  of  more  than  1,200  patients  with
IBS,  63%  were  interested  in  knowing  which  foods  to  avoid.
In  fact,  in  relation  to  lifestyle  changes,  the  aspects  patients
put  in  ﬁrst  place  were  eating  small  meals,  increasing  ﬁber
intake,  and  avoiding  fats,  carbohydrates,  dairy  products,
caffeine,  alcohol,  and  high  protein  foods,  such  as  meat.3 In
addition,  many  IBS  patients  believe  they  have  food  allergies,
even  though  these  are  actually  very  rare.4 Nevertheless,  the
majority  of  food-related  IBS  symptoms  appear  to  be  trig-
gered  by  food  intolerance.
In  the  last  few  years,  sensitivity  to  gluten  and  the
fermentable  oligosaccharides,  disaccharides,  monosaccha-
rides,  and  polyols  (FODMAPs)  has  become  the  main  research
objective  as  a  dietary  cause  of  IBS  symptoms.  In  fact,  the
most  recent  review  carried  out  by  the  American  College
of  Gastroenterology  for  establishing  IBS  treatment  recom-
mendations  published  in  2014  concluded  that  ‘‘specialized
diets  can  improve  symptoms  in  individual  IBS  cases’’.  How-
ever,  this  recommendation  was  graded  as  weak,  due  to  the
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he  review’s  publication.5 In  the  monograph  summary  it  was
tated  that,  albeit  belatedly,  studies  have  ﬁnally  begun  to
nalyze  the  role  of  dietary  factors  in  IBS  pathogeny.  They
ocus  mainly  on  2  mechanisms,  intolerance  and  hypersen-
itivity,  but  others,  such  as  intestinal  hormone  stimulation
nd  interaction  with  the  microbiota,  should  not  be  ruled
ut.  The  summary  ended  by  stating  that  a gluten-free  and
ow  FODMAP  diet  is  promising,  but  its  exact  role  in  IBS  man-
gement  needs  to  be  deﬁned.5
In  this  sense,  these  two  dietary  factors  are  worth  empha-
izing.  First,  I  will  refer  to  the  role  of  gluten.  In  an
nteresting  review  on  celiac  disease  (CD)  and  non-celiac
luten  sensitivity  (NCGS),  Aziz  et  al.  give  a  historical  account
ointing  out  that  human  exposure  to  wheat  began  only
0,000  years  ago  in  Southwest  Asia,  and  its  expansion  lasted
p  to  the  year  4000  B.C.E.6 In  relation  to  the  latter,  it  was
n  the  1940s  that  efforts  were  begun  to  increase  the  pro-
uction  of  wheat,  which  was  achieved  at  the  end  of  the
0th  century,  with  a  5-fold  greater  output.  Thus  wheat  can
e  considered  a  ‘‘new’’  addition  to  the  human  diet,  being
 possible  cause  of  an  immunologic  reaction  in  genetically
usceptible  subjects,  leading  to  the  presence  of  CD  and
CGS  in  those  individuals.6 CD  is  characterized  by  chronic
nﬂammation  of  the  proximal  small  bowel  mucosa  that  cica-
rizes  when  foods  containing  gluten  are  excluded  from  the
iet  and  recurs  when  they  are  reintroduced.  Gluten  con-
ains  storage  proteins  derived  from  wheat,  barley,  and  rye.
hese  proteins  are  rich  in  glutamine  and  proline  and  are
artially  digested  in  the  upper  gastrointestinal  tract,  result-
ng  in  peptides  that  can  trigger  an  immunologic  reaction.7
he  diagnosis  can  be  made  through  the  presence  of  type  IgA
nti-transglutaminase  antibodies  (tTG  IgA)  and  is  conﬁrmed
hrough  biopsies  of  the  small  bowel.  In  10%  of  the  cases,  the
atients  are  seronegative,  due  to  IgA  deﬁciency.  Therefore,
hen  there  are  symptoms  such  as  unexplained  diarrhea  and
 by Masson Doyma México S.A. This is an open access article under
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ron  deﬁciency  anemia,  endoscopy  with  small  bowel  biopsy
hould  be  performed.  The  other  important  diagnostic  com-
onent  is  HLA-DQ2/DQ8,  given  that  100%  of  the  patients
resent  with  these  alleles.  Due  to  their  100%  sensitivity  for
D,  they  are  only  useful  for  disease  exclusion,  because  of
heir  high  negative  predictive  value.7 For  its  part,  NCGS
s  characterized  by  the  presence  of  gastrointestinal  symp-
oms  (e.g.  diarrhea,  pain,  subjective  abdominal  bloating)
nd/or  extraintestinal  symptoms  (e.g.  headache,  fatigue,
rritability,  attention  deﬁcit,  ataxia,  mouth  ulcers)  triggered
y  foods  that  contain  gluten  in  patients  in  whom  CD  or  gluten
llergy  have  been  excluded.  Symptoms  improve  or  disap-
ear  when  gluten  is  suppressed  from  the  diet.  There  are  no
iagnostic  or  serologic  criteria  for  this  disorder  but  some
tudies  have  suggested  the  variable  presence  of  IgA/IgG
nti-gliadins.8 NCGS  has  become  very  popular  and  there  is  an
mpressive  number  of  patients  with  and  without  IBS  in  clin-
cal  practice  that  suspend  gluten  from  the  diet  and  report
ymptom  improvement.  The  turning  point  was  in  2011,  when
iesiekierski  et  al.  published  a  study  in  which  patients  with
BS,  after  a  period  on  a  gluten-free  diet,  were  randomly
ivided  into  a  gluten-free  diet  group  vs  a  group  ingesting
6  g  of  gluten  daily.9 They  found  a  lack  of  adequate  symptom
ontrol  in  68%  of  the  patients  assigned  to  the  gluten  group
s  40%  in  the  gluten-free  diet  group  (p  =  0.0001).  Symptoms
ere  signiﬁcantly  worse  with  gluten  for  abdominal  pain,  sub-
ective  bloating,  fatigue,  satisfaction  with  stool  consistency,
nd  overall  symptoms,  but  not  for  wind  or  nausea.9 The
ame  group  published  a  new  study  2  years  later,  considered
 ‘‘correction  to  the  previous  study’’,  that  was  conducted
n  patients  with  IBS  according  to  the  ROME  III  criteria  and
n  NCGS  patients.  They  underwent  a  low  FODMAP  diet  for  2
eeks,  resulting  in  signiﬁcant  symptom  reduction.10 These
atients  were  then  randomly  divided  into  a  high  gluten  diet
16  g/day)  group  vs  those  on  a  low-gluten  diet  (2  g/day)  plus
4  g  of  whey  protein.  This  was  followed  by  a  washout  period
nd  a  3-day  crossover  treatment.  They  showed  that  the  high
luten  diet,  and  not  the  low  gluten  diet  and/or  placebo,  was
igniﬁcantly  superior  in  relation  to  overall  improvement,
loating,  stool  consistency  satisfaction,  and  wind,  as  well
s  a  trend  in  relation  to  abdominal  pain.  But  there  were  no
ffects  on  tiredness  and  nausea.10 The  above  indicates  that
he  majority  of  patients  that  report  sensitivity  to  gluten,
n  fact,  present  with  an  intolerance  to  FODMAPs,  proba-
ly  a  product  of  the  fructans--which  are  oligosaccharides
FODMAPs)  present  in  wheat--and  not  to  gluten  as  such.11
his  has  been  shown  in  later  studies  by  other  research
roups.12
At  present,  there  is  no  test  for  the  diagnosis  of  intol-
rance  to  FODMAPs  and  perhaps  only  the  fructose  breath
est  can  be  useful  in  a  subgroup  of  patients.13 In  clinical
ractice,  the  most  useful  test  is  probably  a  low  FODMAP
iet  guided  by  a  nutritionist  and  progressive  food  reintroduc-
ion  for  determining  speciﬁc  intolerances.  Both  adherence
o  these  diets  and  their  effectiveness  is  high  in  the  majority
f  patients  that  use  them.  However,  caution  should  be  exer-
ised,  given  that  some  low  FODMAP  diets  have  important
robiotic  effects  on  health.  The  decrease  in  fermentable
ubstrates  arriving  at  the  colon  can  have  at  least  theoretical
mplications  in  relation  to  carcinogenesis  and  inﬂammation,
nd  the  low  FODMAP  diet  reduces  a  variety  of  important
utritional  components  as  well.14
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In  Mexico,  there  are  currently  no  data  on  the  sensitivity
o  FODMAPs  in  patients  with  IBS.  Only  one  national  mul-
icenter  study  interviewing  more  than  1,670  IBS  patients
ound  that  57%  reported  symptoms  with  legumes  (galactans,
ructans?)  and  57%  with  dairy  products  (lactose)  as  symp-
om  triggers,  which  were  only  behind  high  fat  content  foods
72%)  and  spicy  or  strongly  seasoned  foods  (70%)  as  the  most
requent.  No  association  was  found  with  artiﬁcial  sweeten-
rs  (polyols?).15 Nevertheless,  it  should  be  mentioned  that
n  our  clinical  practice  we  see  many  patients  with  IBS  that
eport  symptoms  such  as  bloating,  ﬂatulence,  abdominal
ain  and/or  diarrhea  and  that  also  have  the  custom  of
hewing  gum.  Currently,  the  majority  of  chewing  gums  are
weetened  with  sorbitol,  followed  by  isomaltol  and  maltitol
polyols),  and  the  gum-chewing  patients  improve  simply  by
topping  the  habit.
In  this  issue  of  the  Revista  de  Gastroenterología  de  Méx-
co,  Pérez  y  López  et  al.  present  the  ﬁrst  study  in  Mexico
n  IBS  patients  treated  with  a  low  FODMAP  diet  (<  0.50  g
er  meal)  for  21  days.  Thirty-one  patients  were  included,
f  which  87%  were  women.  The  patients  were  given  a  list
f  ‘‘prohibited’’  foods  during  the  treatment  period.  The
uthors  found  a  signiﬁcant  reduction  in  pain,  abdominal
loating,  and  ﬂatulence  evaluated  through  visual  analogue
cales.  In  addition,  29.0%  reported  complete  treatment
atisfaction,  25.8%  moderate  satisfaction,  16.1%  slight  sat-
sfaction,  16%  no  changes,  and  12.9%  dissatisfaction.  No
hanges  were  found  in  stool  consistency  evaluated  through
he  Bristol  Scale.16
Even  though  this  is  a  ﬁrst  analysis  in  our  environment,
he  results  should  be  interpreted  with  care,  given  that  the
tudy  has  certain  limitations,  as  do  the  majority  of  stud-
es  evaluating  dietary  interventions  in  IBS.  Despite  the  fact
hat  the  authors  describe  their  study  as  a  ‘‘comparative’’
nalysis,  the  most  important  limitation  is  precisely  the  lack
f  a  control  group  that  included  the  average  or  regular
iet  of  the  study  population,  with  both  diets  having  the
ame  nutritional  content.17 In  regard  to  dietary  interven-
ion  trials,  the  Rome  Foundation’s  Working  Group  on  the
ole  of  Foods  in  Functional  Gastrointestinal  Disorders  has
ecently  recommended  as  the  ideal,  a  double-blind,  con-
rolled  design  that  includes  a  food  challenge.  However,  on
he  one  hand,  there  is  the  difﬁculty  of  suitable  masking,
s  is  to  be  expected  with  this  type  of  intervention,  and  on
he  other  hand,  there  must  be  an  adequate  washout  period
efore  the  food  challenge  is  then  gradually  introduced.17
t  is  also  recommended  to  describe  the  presence  of  active
reatments  in  both  groups  and  the  history  of  reactions  to
oods  or  the  perception  of  food  intolerances,  adherence  to
he  dietary  intervention,  and  the  presence  of  adverse  events
elated  to  the  study  diet.  There  should  also  be  a  dietician  in
he  group  and  the  analysis  should  be  controlled  for  factors
hat  can  interact  with  the  food  challenge,  such  as  concomi-
ant  medication  use,  alcohol,  and  physical  activity,  among
thers.17 None  of  these  have  been  described  by  Pérez  y
ópez  et  al.16
In  conclusion,  even  though  the  data  in  the  literature  sug-
est  that  the  majority  of  patients  with  NCGS,  in  fact,  present
ith  intolerance  or  sensitivity  to  FODMAPs  and  that  a  diet
ow  in  these  fermentable  carbohydrates  and  polyols  can
mprove  IBS  symptoms  in  the  patients  that  use  it,  this  diet
hould  be  administered  under  the  supervision  of  an  expert
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nutritionist.  Furthermore,  the  designs  used  in  the  major-
ity  of  studies  that  have  evaluated  the  low  FODMAP  diet  in
IBS  are  not  adequate  for  arriving  at  a  solid  conclusion  with
respect  to  the  effectiveness  of  this  intervention.
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